CS-179mixed
Fisher & Paykel Healthcare Corporation Limited (Auckland, New Zealand), maker of respiratory and sleep-apnoea devices listed on the NZX and ASX
Second manufacturing base in Tijuana, Mexico, alongside Auckland (2009-2025)
- Region
- Oceania, Latin America, North America
- Country
- New Zealand, Mexico, United States
- Industry
- Medical and Health Technology (Discrete Manufacturing)
- Functions
- Manufacturing & Production, Supply Chain & Logistics, Operations & Service Delivery, Treasury & Working Capital, Strategy, Corporate Development & Transformation Office, HR & Workforce
- Topics
- Margins are eroding despite revenue; Supply chain disruption has made the network fragile; Operations cannot meet demand efficiently; Energy, resource or climate exposure undermines economics
- Starting situation
- New initiative
- Period
- 2009–2025
- Last verified
- 5 November 2026
Executive summary
In 2009 Fisher & Paykel Healthcare made almost everything it sold in Auckland and exported 99% of it, mostly for US dollars and euros [C01, C02]. It leased a site in Tijuana, Mexico, to add capacity for its high-volume consumables (masks, breathing circuits and humidifier chambers) closer to North America and at lower and more stable labour cost [C01, C05, C06].
It grew Mexico by adding capacity there rather than moving work out of New Zealand: a first leased plant in 2010, a second building on its own land in 2019 and a third in 2023, with more than 950 staff in Tijuana by 2017 [C06, C09, C10, C13].
The numbers that matter: by 2025 Mexico made about 45% of the company's volume and about 60% of its US volume [C15]; gross margin rose from 53.9% in FY2010 to about 66% in late 2017, with the company crediting Mexican volume [C01, C08]. The aim of making about half of consumable volume in Mexico within three years of 2014 was not reported met on the measures found [C04, C08, C15]. The lesson: a second plant built for growth rather than relocation can raise margin and spread risk without the disruption of closing the first.
Outcome: mixed
Documented shortfalls or reversals sit alongside documented gains. For example: an initial failure later recovered, or a strategic goal met while a major adverse event in the same programme was recorded.
Basis of the outcome
The stated aims were to add manufacturing capacity for high-volume consumables in a second, lower-cost location close to North America, with geographic diversity, and to improve margins (S02, S03, S05). The plant began production in 2010, contributed to operating margin from 2011, and was expanded with a second building in 2019 and a third in 2023 (S02, S03, S04, S09, S12, S13). By 2025 about 45% of the company's volume and about 60% of its US volume came from Mexico, and practically all finished goods made there were USMCA-compliant (S14, S17). Gross margin rose from 53.9% (FY2010) to about 66% (late 2017), with the company crediting Mexican volume (S01, S06, S07). A dated aim was missed: in 2014 the company expected Mexico to make about half of its consumable volume within three years (S04, S05), and the share reported later was about 35% of production in 2017 and about 45% of volume in 2025 (S07, S14). The programme was not reversed, written down or abandoned; its core aims met alongside a dated aim not reported met meet the mixed criterion.
Key figures
| Phase | Figure | Value | When | Verification |
|---|---|---|---|---|
| Before | Operating revenue | NZ$503.3m (US$341.5m) | FY2010 | company_reported |
| Before | Gross margin | 53.9% | FY2010 | company_reported |
| Before | Initial investment in Tijuana | about NZ$20m | FY2010 | company_reported |
| During | Planned annual savings | NZ$20m | Aug 2011 | press_reported |
| During | Target share of consumable volume | about half within three years | Feb 2014 | company_reported |
| During | Mexico employees | 487 | Mar 2014 | company_reported |
| During | Mexico share of production | about 35% | Nov 2017 | press_reported |
| During | Gross margin | about 66% | Nov 2017 | press_reported |
| After | Mexico share of volume | about 45% | Feb 2025 | company_reported |
| After | US volume supplied from Mexico | about 60% | Feb 2025 | company_reported |
| After | Gross margin | 62.9% | FY2025 | press_reported |
- company_reported
- A company statement, press release or investor presentation that no one has independently checked.
- press_reported
- A journalist's own reporting.
Practices this case bears on
- SupportsMake a few quantified, dated commitments, publish them, and report against them, including the misses BP-004
- SupportsRoll out operational and system change in waves, each proven before the next BP-006
- SupportsSecure the scarce delivery skills early, and build the pipeline in-house when the market cannot supply it BP-018
- SupportsDefine and freeze each programme metric before reporting it, and keep it comparable BP-034
- SupportsTreat regulators and the state as design constraints from day one, with priced remedies and a fallback BP-041
- SupportsPlan workforce change as a funded people programme: delayer first, share the upside, and redeploy where you can BP-049
- SupportsPlan on the downside: assume the legacy business declines faster and the cycle turns, and have the cost playbook ready BP-054
- SupportsTest whether your capabilities really transfer before betting on a new market or exporting a model BP-056
- SupportsTransform from strength, with a protected multi-year funding envelope or self-funding productivity BP-063
- SupportsMap critical dependencies several tiers deep, buffer what cannot be re-sourced, and decide who pays for resilience BP-064
Sources
- S01 Fisher & Paykel Healthcare reports 15% growth in profit to NZ$71.6m · Fisher & Paykel Healthcare Corporation Limited, Fisher & Paykel Healthcare, 2010-05-26 · accessed 2026-11-04
- S02 Fisher & Paykel Healthcare Annual Shareholders' Meeting Speeches · Gary Paykel (chair) and Michael Daniell (chief executive), Fisher & Paykel Healthcare, 2010-08-27 · accessed 2026-11-04
- S03 F&P Healthcare flees from over-valued kiwi, trims guidance · Jonathan Underhill, Scoop (BusinessDesk), 2011-08-19 · accessed 2026-11-04
- S04 Fisher & Paykel Healthcare lifts earnings guidance, announces Mexico manufacturing expansion · Fisher & Paykel Healthcare Corporation Limited, Fisher & Paykel Healthcare, 2014-02-18 · accessed 2026-11-04
- S05 Mexico and US presentation (site visit) · Fisher & Paykel Healthcare Corporation Limited, Fisher & Paykel Healthcare, 2014-09-22 · accessed 2026-11-04
- S06 Fisher & Paykel Healthcare Reports Record Annual Result, Net Profit Up 18% · Fisher & Paykel Healthcare Corporation Limited, Fisher & Paykel Healthcare, 2017-05-22 · accessed 2026-11-04
- S07 Bright outlook for F&P Healthcare · Dene Mackenzie, Otago Daily Times, 2017-11-21 · accessed 2026-11-04
- S08 Fisher & Paykel Healthcare building programme underway in New Zealand · Fisher & Paykel Healthcare Corporation Limited, Fisher & Paykel Healthcare, 2017-12-18 · accessed 2026-11-04
- S09 Fisher & Paykel Healthcare commences planning for new manufacturing facility · Fisher & Paykel Healthcare Corporation Limited, Fisher & Paykel Healthcare, 2020-08-21 · accessed 2026-11-04
- S10 FPH announces its results for FY2023 · Fisher & Paykel Healthcare Corporation Limited, Fisher & Paykel Healthcare, 2023-05-26 · accessed 2026-11-04
- S11 F&P Healthcare emerges from Covid era with 34pc profit fall · Jamie Gray, The New Zealand Herald, 2023-05 · accessed 2026-11-04
- S12 Fisher & Paykel Healthcare celebrates the opening of the Sánchez Building · Fisher & Paykel Healthcare Corporation Limited, Fisher & Paykel Healthcare, 2023-09 · accessed 2026-11-04
- S13 Fisher & Paykel Opens Third Manufacturing Facility in Tijuana · Sleep Review Staff, Sleep Review, 2023-09-20 · accessed 2026-11-04
- S14 Costs forecast to increase under new US tariff regime · Fisher & Paykel Healthcare Corporation Limited, ASX announcements platform, 2025-02-03 · accessed 2026-11-04
- S15 F&P 'working through complexities' of new tariffs · HME News Staff, HME News, 2025-02-03 · accessed 2026-11-04
- S16 Costs forecast to rise under new tariff regime · not stated, Times (New Zealand), 2025-02 · accessed 2026-11-04
- S17 Fisher & Paykel Breaks $2 Billion Revenue Mark with Growth in OSA Masks, Hospital Consumables · Laurie Watanabe, HME Business, 2025-05-30 · accessed 2026-11-04
Researched and fact-checked knowledgebase · Knowledgebase built 5 November 2026 · Last verified 5 November 2026
Practices, their evidence grades and case summaries are public. Full case studies are available in AXIOM to subscribers and AXIOM Discover participants.

